Clinical value of immunochemotherapy with OK-432 or PS-K for stomach cancer patients

A prospective clinical trial was undertaken in 121 patients with stomach cancer to compare immunochemotherapy with 5-fluorouracil and FT-207 combined with OK-432 or PS-K, immunostimulators, and plain chemotherapy with 5-fluororacil and FT-207. Of the 121 patients who received immunochemotherapy, 67...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of surgery 1979-09, Vol.9 (3), p.190-196
Main Authors: Fujimoto, S, Takahashi, M, Minami, T, Ishigami, H, Miyazaki, M, Itoh, K
Format: Article
Language:English
Subjects:
Adult
Aged
Antibiotics, Antineoplastic - therapeutic use
Biological Products - therapeutic use
Dinitrochlorobenzene - immunology
Drug Therapy, Combination
Fluorouracil - therapeutic use
Humans
Immunotherapy
Lymphocyte Activation
Middle Aged
Phytohemagglutinins - pharmacology
Picibanil - therapeutic use
Proteoglycans - therapeutic use
Skin Tests
Stomach Neoplasms - immunology
Stomach Neoplasms - mortality
Stomach Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A prospective clinical trial was undertaken in 121 patients with stomach cancer to compare immunochemotherapy with 5-fluorouracil and FT-207 combined with OK-432 or PS-K, immunostimulators, and plain chemotherapy with 5-fluororacil and FT-207. Of the 121 patients who received immunochemotherapy, 67 patients (group A) had undergone curative removal of the tumor. The other 54 patients had undergone noncurative tumor removal or had recurrence after non-curative tumor removal and they were divided into two groups (groups B and C) on the basis of lymphocyte reactivity induced with PHA. Although group A exhibited a significant increase in PHA-induced lymphocyte transformation and a trifling increase in lymphocyte counts, its survival rate within a 36 month period did not differ from that of the peer controls. Group B, composed of 21 patients showing improvement of PHA-induced lymphocyte transformation, significantly prolonged its survival compared to the peer controls. The survival of group C, composed of 33 patients showing a gradual drop in PHA-induced lymphocyte transformation, was not prolonged compared to the peer control patients; and they showed significant decreases in lymphocyte counts. The overall survival of group B and group C was not superior to that of the 48 peer controls.
ISSN:0047-1909
1436-2813
DOI:10.1007/BF02469420